AI Article Synopsis
- - The study aimed to assess how effective adalimumab is for treating patients with refractory non-infectious uveitis, focusing on changes in retinal vascular leakage.
- - Involved 23 patients and analyzed a total of 44 eyes, finding that a significant portion had active inflammation, and measuring changes in drug usage and eye conditions over time.
- - Results showed that adalimumab effectively reduced inflammation and retinal leakage, suggesting it is a beneficial treatment for patients with this eye condition.
Article Abstract
Aim: To investigate the efficacy of adalimumab in the cases with refractory non-infectious uveitis and evaluate retinal vascular leakage changes on ultra-widefield fundus fluorescein angiography.
Methods: Twenty-three patients with refractory uveitis were included in study.
Results: Forty-four eyes of 23 patients with non-infectious uveitiswere evaluated. Clinically active inflammation was present in 19 eyes (43.18%), while 25 (56.8%) were inactive. The mean drug burden was a 9.91 ± 3.78 (5-21) in baseline, 7.3 ± 4.25 at third and 8.0 ± 4.71 at sixth month (p = 0.022). The mean choroidal thickness was 256.65 ± 43.63 μm in baseline, 240.49 ± 36.73 μm at third and 224.81 ± 34.91 μm at sixth month (p ≤ 0.05). In terms of leakage extend, leakage was initially present in a mean of 2.95 ± 4.55 clock hours, 2.41 ± 3.91 at third and 1.76 ± 3.44 at sixth month (p < 0.001).
Conclusion: Adalimumab was found to be effective in establishing inflammation control by reducing drug burden, controlling retinal vascular leakage and choroidal inflammation in refractory uveitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10792-021-02209-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!